Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.
Nicole O. Williams, MD
Advertisement
Articles by Nicole O. Williams, MD
Nicole O. Williams, MD, discusses treatment considerations for selecting between CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.
Advertisement
Latest Updated Articles
Dr. Williams on Selecting Between CDK4/6 Inhibitors in HR+/HER2- Breast CancerPublished: April 29th 2021 | Updated:
Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast CancerPublished: July 1st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5